Previous 10 | Next 10 |
Annovis shares sank by ~60% yesterday after the company presented additional data from a study of its lead drug Posiphen in 14 Alzheimer's and 14 Parkinson's patients. Promising data released in May had shown a 4.4 point increase in the cognitive scoring system ADAS-Cog11. Better than...
ANVS401's Interim Clinical Data Demonstrate Statistically Significant Improvements in Cognitive Function in AD Patients and Motor Function in PD Patients Biomarkers Demonstrate Reduction in Neurotoxic Proteins, Improvement in Axonal Health and Reduction in Inflammation Levels Next Clin...
A group of biotech companies focused on developing treatments for Alzheimer’s disease is trading lower in the pre-market continuing their losses on Thursday following updates to their development programs. Cassava Sciences (NASDAQ:SAVA) has lost ~16.2% in early trading after ...
Pinterest (NYSE:PINS) -20% on Q2 earnings release Cassava Sciences (NASDAQ:SAVA) -17% despite presenting 'positive' data on simufilam for Alzheimer's 360 DigiTech (NASDAQ:QFIN) -12%. Annovis Bio (NYSE:ANVS) -11%. Uxin (NASDAQ:UXIN) -11% on Q4 earnings release. Le...
On July 28, Annovis Bio released new clinical and biomarker data from their two p2a trials in Alzheimer's disease (AD) and Parkinson's disease (PD) at 2021 AAIC. The stock of ANVS has gone up >1200% YTD (from $8.15 on Jan 4 to $109.44 on July 28), due to the positive early data of ...
Shares of Annovis Bio (NYSEMKT: ANVS) are getting hammered in response to disappointing data for the company's Alzheimer's disease candidate. The biotech stock was down 59.4% at 2:45 p.m. EDT. Annovis Bio's losses have spread to other clinical-stage biotech companies with Alzhei...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of Annovis Bio (NYSEAMERICAN: ANVS ) stock are crashing hard today after some disappointing results from its Alzheimer’s disease treatment trials. Source: Atthapon Raksthaput / Shutterstock.com T...
Gainers: Intec Pharma (NASDAQ:NTEC) +61%. LendingClub Corporation (NYSE:LC) +55%. NanoVibronix (NASDAQ:NAOV) +36%. Golden Star Resources (NYSE:GSS) +28%. Dream Finders Homes (NASDAQ:DFH) +17%. E-Home Household Service Holdings (NASDAQ:EJH) +17%. Tempur Sealy International (NYSE:TPX) +16%. Hut...
Gainers: NanoVibronix (NASDAQ:NAOV) +49%, Intec Pharma (NASDAQ:NTEC) +31%, Cocrystal Pharma (NASDAQ:COCP) +17%, Burning Rock Biotech (NASDAQ:BNR) +11%, Genetron (NASDAQ:GTH) +8%. Losers: Annovis Bio (NYSE:ANVS) -48%, Atreca (NASDAQ:BCEL) -35%,...
Annovis Bio, Inc. (NYSE:ANVS) -53% after presenting Alzheimer's drug data at AAIC 2021. Atreca, Inc. (NASDAQ:BCEL) -29% after presents initial clinical data from Phase 1b trial of ATRC-101 in select advanced solid tumors. Citrix Systems, Inc. (NASDAQ:CTXS) -16% on Q2 ...
News, Short Squeeze, Breakout and More Instantly...
Annovis Bio (NYSE: ANVS) , a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced the receipt of U.S. Patent No. 12,042,482. The patent ...
MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’...
The new executive team includes Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen These additions are pivotal as the company makes strides toward bringing flagship drug candidate buntanetap closer to New Drug Application (“NDA”) status and to market Annovis Bio (NYS...